Read by QxMD icon Read


Hsiang-Yin Chen, Pei-Yin Chiu, Ching-Jun Chang, Lih-Ling Tsai, Ya-Lan Huang, Jason C Hsu
BACKGROUND AND OBJECTIVES: A new oral antidiabetic drug class, sodium-glucose co-transporter-2 inhibitors (SGLT-2 inhibitors), has been covered by national health insurance in Taiwan since May 2016. This study estimated the impacts of insurance coverage for SGLT-2 inhibitors on the replacement effects of antidiabetic drug use and the overall budget for antidiabetic drugs in Taiwan. METHODS: Antidiabetic drugs were divided into nine categories based on the American Diabetes Association guidelines...
September 15, 2018: Clinical Drug Investigation
Andrew Tinker, Qadeer Aziz, Yiwen Li, Mark Specterman
ATP sensitive potassium channels (KATP ) are so named because they open as cellular ATP levels fall. This leads to membrane hyperpolarization and thus links cellular metabolism to membrane excitability. They also respond to MgADP and are regulated by a number of cell signaling pathways. They have a rich and diverse pharmacology with a number of agents acting as specific inhibitors and activators. KATP channels are formed of pore-forming subunits, Kir6.1 and Kir6.2, and a large auxiliary subunit, the sulfonylurea receptor (SUR1, SUR2A, and SUR2B)...
September 14, 2018: Comprehensive Physiology
Ayush Sharma, Suresh T Chari
PURPOSE OF REVIEW: The relationship between pancreatic ductal adenocarcinoma (PDAC) and diabetes mellitus (DM) is complex. We reviewed the recent medical literature regarding the effect of anti-diabetic medication on PDAC risk and survival, risk of PDAC in DM, and role of DM in early detection of PDAC. RECENT FINDINGS: Studies report that while some anti-diabetic medications (e.g., metformin) may decrease the risk of PDAC, others (insulin, sulfonylureas and incretin-based therapies) may increase the risk...
September 13, 2018: Current Treatment Options in Gastroenterology
Yeon Young Cho, Sung-Il Cho
A complex comorbidity status may cause treatment variance interfering with type 2 diabetes (T2D) guideline-confirm therapy and influence the occurrence of complications but evidence on its relationships and alternative treatments are lacking. This study aimed to identify treatment variance and common T2D drug treatment related to comorbid status and the association with comorbidity and complications.Based on Korean National Health Insurance Service-National Sample Cohort (NHIS-NSC) databases, we conducted a retrospective, observational exploratory study including 7123 T2D patients without microvascular-, macrovascular complication...
September 2018: Medicine (Baltimore)
Nathan K Itoga, Kara A Rothenberg, Paola Suarez, Thuy-Vy Ho, Matthew W Mell, Baohui Xu, Catherine M Curtin, Ronald L Dalman
BACKGROUND: Identification of a safe and effective medical therapy for abdominal aortic aneurysm (AAA) disease remains a significant unmet medical need. Recent small cohort studies indicate that metformin, the world's most commonly prescribed oral hypoglycemic agent, may limit AAA enlargement. We sought to validate these preliminary observations in a larger cohort. METHODS: All patients with asymptomatic AAA disease managed in the Veterans Affairs Health Care System between 2003 and 2013 were identified by International Classification of Diseases, Ninth Revision codes...
September 6, 2018: Journal of Vascular Surgery
Ronald M Goldenberg, Oren Steen
Guidelines increasingly highlight the importance of multifactorial management in type 2 diabetes, in contrast to the more traditional focus on glycemic control. Semaglutide, a recently approved glucagon-like peptide-1 receptor agonist, is indicated in Canada for adults with type 2 diabetes to improve glycemic control as monotherapy with diet and exercise when metformin is inappropriate or as an add-on to either metformin alone or metformin plus a sulfonylurea or basal insulin. The Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) clinical trial program for semaglutide comprises 6 pivotal global phase 3a trials (SUSTAIN 1 through 6) and 2 Japanese phase 3a trials...
June 5, 2018: Canadian Journal of Diabetes
Sarah E Petite
PURPOSE: Published evidence regarding the role of noninsulin antidiabetic therapies in glycemic management of hospitalized patients with diabetes mellitus is reviewed. SUMMARY: The American Diabetes Association recommends against the routine use of noninsulin antidiabetic therapies during hospitalization and supports insulin use instead. There are significant risks associated with insulin therapy, including hypoglycemia, and use of alternative therapies may be considered in hospitalized patients...
September 15, 2018: American Journal of Health-system Pharmacy: AJHP
Naina Mohamed Pakkir Maideen, Gobinath Manavalan, Kumar Balasubramanian
Meglitinides such as repaglinide and nateglinide are useful to treat type 2 diabetes patients who follow a flexible lifestyle. They are short-acting insulin secretagogues and are associated with less risk of hypoglycemia, weight gain and chronic hyperinsulinemia compared with sulfonylureas. Meglitinides are the substrates of cytochrome P450 (CYP) enzymes and organic anion transporting polypeptide 1B1 (OATP1B1 transporter) and the coadministration of the drugs affecting them will result in pharmacokinetic drug interactions...
2018: Therapeutic Advances in Endocrinology and Metabolism
Rui Zhang, Xiaojun Zhou, Xue Shen, Tianyue Xie, Chunmei Xu, Zhiwei Zou, Jianjun Dong, Lin Liao
BACKGROUND: Sulfonylureas (SUs) are widely prescribed for the treatment of type 2 diabetes (T2DM). Sulfonylurea receptors (SURs) are their main functional receptors. These receptors are also found in kidney, especially the tubular cells. However, the effects of SUs on renal proximal tubular epithelial cells (PTECs) were unclear. METHODS: Three commonly used SUs were included in this study to investigate if different SUs have different effects on the apoptosis of PTECs...
September 4, 2018: Molecular Medicine
Gojka Roglic, Susan L Norris
Description: The World Health Organization developed these guidelines to provide guidance on selection of medicines for treatment intensification in type 2 diabetes and on use of insulin (human or analogue) in type 1 and 2 diabetes. The target audience includes clinicians, policymakers, national diabetes program managers, and medicine procurement officers. The target population is adults with type 1 or 2 diabetes in low-resource settings in low- or high-income countries. The guidelines also apply to disadvantaged populations in high-income countries...
September 4, 2018: Annals of Internal Medicine
Samantha V Wilkinson, Laurie A Tomlinson, Masao Iwagami, Heide A Stirnadel-Farrant, Liam Smeeth, Ian Douglas
Background : The development of kidney disease is a serious complication among people with type 2 diabetes mellitus, associated with substantially increased morbidity and mortality.  We aimed to summarise the current evidence for the relationship between treatments for type 2 diabetes and long-term kidney outcomes, by conducting a systematic search and review of relevant studies. Methods : We searched Medline, Embase and Web of Science, between 1st January 1980 and 15th May 2018 for published clinical trials and observational studies comparing two or more classes of oral therapy for type 2 diabetes...
2018: Wellcome Open Research
Jordi Caballero-Corchuelo, Fernando Guerrero-Pérez, Paula García-Sancho de la Jordana, Manuel Pérez-Maraver
INTRODUCTION AND OBJECTIVE: Hypoglycemia associated to insulin or other glucose-lowering agents is one of the most common causes of visits to the emergency department for adverse drug reactions. The study objective was to analyze the characteristics of patients with diabetes mellitus (DM) who attend a tertiary hospital emergency department for a hypoglycemic event. PATIENTS AND METHODS: A 3-year retrospective analysis was conducted of patients with DM who attended the emergency department of Hospital Universitari de Bellvitge for a hypoglycemic event...
August 29, 2018: Endocrinología, Diabetes y Nutrición
Qian Zhang, Chengwu Li, Ting Zhang, Yaping Ge, Xiaojuan Han, Sifan Sun, Jianhua Ding, Ming Lu, Gang Hu
ATP-sensitive potassium (K-ATP) channels express in the central nervous system extensively which coupling cell metabolism and cellular electrical activity. K-ATP channels in mature substantia nigra (SN) dopaminergic (DA) neurons are composed of inwardly rectifying potassium channel (Kir) subunit 6.2 and sulfonylurea receptor 1 (SUR1). Our previous study revealed that regulating K-ATP channel exerts the protective effect on DA neurons in a mouse model of Parkinson's disease (PD). However, the detailed mechanism underlying the role of Kir6...
August 29, 2018: Molecular and Cellular Neurosciences
Clara K Chow, Chinthanie Ramasundarahettige, Weihong Hu, Khalid F AlHabib, Alvaro Avezum, Xiaoru Cheng, Jephat Chifamba, Gilles Dagenais, Antonio Dans, Bonaventure A Egbujie, Rajeev Gupta, Romaina Iqbal, Noorhassim Ismail, Mirac V Keskinler, Rasha Khatib, Lanthé Kruger, Rajesh Kumar, Fernando Lanas, Scott Lear, Patricio Lopez-Jaramillo, Martin McKee, Noushin Mohammadifard, Viswanathan Mohan, Prem Mony, Andres Orlandini, Annika Rosengren, Krishnapillai Vijayakumar, Li Wei, Karen Yeates, Khalid Yusoff, Rita Yusuf, Afzalhussein Yusufali, Katarzyna Zatonska, Yihong Zhou, Shariful Islam, Daniel Corsi, Sumathy Rangarajan, Koon Teo, Hertzel C Gerstein, Salim Yusuf
BACKGROUND: Data are scarce on the availability and affordability of essential medicines for diabetes. Our aim was to examine the availability and affordability of metformin, sulfonylureas, and insulin across multiple regions of the world and explore the effect of these on medicine use. METHODS: In the Prospective Urban Rural Epidemiology (PURE) study, participants aged 35-70 years (n=156 625) were recruited from 110 803 households, in 604 communities and 22 countries; availability (presence of any dose of medication in the pharmacy on the day of audit) and medicine cost data were collected from pharmacies with the Environmental Profile of a Community's Health audit tool...
August 28, 2018: Lancet Diabetes & Endocrinology
Yi-Sheng Liou, Fu-Yu Yang, Hung-Yi Chen, Gwo-Ping Jong
Currently, the potential risk of atrial fibrillation associated with antihyperglycemic drug use has been a topic of considerable interest. However, it remains uncertain whether different classes of antihyperglycemic drug therapy are associated with the risk of atrial fibrillation risk. Here, we investigated the association between different classes of antihyperglycemic drugs and new-onset atrial fibrillation (NAF). A case-matched study was performed based on the National Health Insurance Program in Taiwan. Patients who had NAF were considered the NAF group and were matched in a 1:4 ratio with patients without NAF, who were assigned to the non-NAF group...
2018: PloS One
Volodymyr Gerzanich, Jesse Stokum, Svetlana Ivanova, S Kyoon Woo, Orest Tsymbalyuk, Amit Sharma, Fatih Akkentli, Ziyan Imran, Bizhan Aarabi, Juan Sahuquillo, J Marc Simard
In severe traumatic brain injury (TBI), contusions often are worsened by contusion expansion, or "hemorrhagic progression of contusion" (HPC), which may double the original contusion volume and worsen outcome. In humans and rodents with contusion-TBI, sulfonylurea receptor 1 (SUR1) is upregulated in microvessels and astrocytes, and in rodent models, blockade of SUR1 with glibenclamide reduces HPC. SUR1 does not function by itself, but must co-assemble with either KIR6.2 or TRPM4 to form KATP (SUR1-KIR6...
August 30, 2018: Journal of Neurotrauma
Yehuda Handelsman, Kathleen Wyne, Anthony Cannon, Michael Shannon, Doron Schneider
This article provides an overview of the efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the treatment of type 2 diabetes mellitus (T2DM). GLP-1 RAs stimulate pancreatic GLP-1 receptors, which increases insulin secretion, delays gastric emptying, and increases satiety. As a class, GLP-1 RAs lower A1c levels and have been associated with reductions in weight and blood pressure and reduced fluctuations in glucose levels, and they have a low risk of hypoglycemia. Exenatide extended release (ER) and dulaglutide monotherapy have shown similar or superior reductions in A1c and weight compared with various oral antidiabetic drugs (OADs)...
September 2018: Journal of Managed Care & Specialty Pharmacy
Xiaoling Cai, Xueying Gao, Wenjia Yang, Xueyao Han, Linong Ji
INTRODUCTION: The aim of this study was to evaluate the efficacy and safety of initial combination therapy compared with monotherapy in drug-naïve type 2 diabetes patients. METHODS: MEDLINE, Embase and the Cochrane Central Register of Controlled Trials were searched for randomized clinical trials of initial combination therapy with hypoglycemic agents compared with monotherapy. Those which satisfied the search criteria were included in the meta-analysis. Weighted mean difference and relative risks were calculated...
August 28, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
Dan Qian, Tiantian Zhang, Xiangping Tan, Peiying Zheng, Zhuoru Liang, Jingmei Xie, Jie Jiang, Bing Situ
AIMS: This study aimed to investigate the efficacy and safety of dual therapy comprising sulfonylurea (SU) plus antidiabetic drugs for the treatment of type 2 diabetes mellitus (T2DM). METHODS: We searched the PubMed, Cochrane library, and Embase databases for randomized clinical trials (≥24 weeks) published up to December 28, 2017. Subsequently, we conducted pairwise and network meta-analyses to calculate the odds ratios (ORs) and mean differences (MDs) with 95% confidence intervals (CIs) of the outcomes...
2018: PloS One
Zachary A King, Kevin N Sheth, W Taylor Kimberly, J Marc Simard
Glyburide (also known as glibenclamide) is a second-generation sulfonylurea drug that inhibits sulfonylurea receptor 1 (Sur1) at nanomolar concentrations. Long used to target KATP (Sur1-Kir6.2) channels for the treatment of diabetes mellitus type 2, glyburide was recently repurposed to target Sur1-transient receptor potential melastatin 4 (Trpm4) channels in acute central nervous system injury. Discovered nearly two decades ago, SUR1-TRPM4 has emerged as a critical target in stroke, specifically in large hemispheric infarction, which is characterized by edema formation and life-threatening brain swelling...
2018: Drug Design, Development and Therapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"